Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
2.

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.

Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: Lancet. 2018 Feb 26;:.

PMID:
29429593
3.

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2917-2928. doi: 10.2147/COPD.S146822. eCollection 2017. Review.

4.

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.

Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D.

Int J Chron Obstruct Pulmon Dis. 2017 Jul 7;12:2001-2014. doi: 10.2147/COPD.S137659. eCollection 2017.

5.

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.

Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D.

Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3.

PMID:
28385353
6.

Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.

Singh D, Ciurlia G, Piccinno A, Muraro A, Bocchi M, Scuri M.

Pulm Pharmacol Ther. 2017 Feb;42:43-51. doi: 10.1016/j.pupt.2016.12.004. Epub 2017 Jan 5.

7.

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.

Paggiaro P, Corradi M, Latorre M, Raptis H, Muraro A, Gessner C, Siergiejko Z, Scuri M, Petruzzelli S.

BMC Pulm Med. 2016 Dec 9;16(1):180.

8.

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.

Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.

Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1.

PMID:
27598678
9.

Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.

Crisafulli E, Zanini A, Pisi G, Pignatti P, Poli G, Scuri M, Chetta A.

Expert Rev Respir Med. 2016;10(5):481-90. doi: 10.1586/17476348.2016.1161508. Epub 2016 Mar 16. Review.

PMID:
26938578
10.

Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.

Kuna P, Govoni M, Lucci G, Scuri M, Acerbi D, Stelmach I.

Br J Clin Pharmacol. 2015 Sep;80(3):569-80. doi: 10.1111/bcp.12640. Epub 2015 Jun 1.

11.

Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.

Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S.

Pulm Pharmacol Ther. 2015 Feb;30:121-7. doi: 10.1016/j.pupt.2014.07.006. Epub 2014 Aug 1.

12.

Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Voshaar T, Spinola M, Linnane P, Campanini A, Lock D, Lafratta A, Scuri M, Ronca B, Melani AS.

J Aerosol Med Pulm Drug Deliv. 2014 Oct;27(5):363-70. doi: 10.1089/jamp.2013.1086. Epub 2013 Dec 3.

13.

An unusual case of signet ring cell adenocarcinoma of the prostate.

Bonetti LR, Lupi M, Stauder E, Bergamini S, Scuri M, Maiorana A.

Pathologica. 2011 Apr;103(2):40-2.

PMID:
21797141
14.

Cytomegalovirus infection of the upper gastrointestinal tract: a clinical and pathological study of 30 cases.

Reggiani Bonetti L, Losi L, Di Gregorio C, Bertani A, Merighi A, Bettelli S, Scuri M, Maiorana A.

Scand J Gastroenterol. 2011 Oct;46(10):1228-35. doi: 10.3109/00365521.2011.594083. Epub 2011 Jun 22.

PMID:
21692711
15.

In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid.

Cermelli C, Cuoghi A, Scuri M, Bettua C, Neglia RG, Ardizzoni A, Blasi E, Iannitti T, Palmieri B.

Virol J. 2011 Mar 25;8:141. doi: 10.1186/1743-422X-8-141.

16.

Effects of titanium dioxide nanoparticle exposure on neuroimmune responses in rat airways.

Scuri M, Chen BT, Castranova V, Reynolds JS, Johnson VJ, Samsell L, Walton C, Piedimonte G.

J Toxicol Environ Health A. 2010;73(20):1353-69. doi: 10.1080/15287394.2010.497436.

17.

The role of neurotrophins in inflammation and allergy.

Scuri M, Samsell L, Piedimonte G.

Inflamm Allergy Drug Targets. 2010 Jul;9(3):173-80. Review.

PMID:
20553229
18.

Neurotrophic and neuroimmune responses to early-life Pseudomonas aeruginosa infection in rat lungs.

Cardenas S, Scuri M, Samsell L, Ducatman B, Bejarano P, Auais A, Doud M, Mathee K, Piedimonte G.

Am J Physiol Lung Cell Mol Physiol. 2010 Sep;299(3):L334-44. doi: 10.1152/ajplung.00017.2010. Epub 2010 Jun 11.

19.

Combined effects of chronic nicotine and acute virus exposure on neurotrophin expression in rat lung.

Urrego F, Scuri M, Auais A, Mohtasham L, Piedimonte G.

Pediatr Pulmonol. 2009 Nov;44(11):1075-84. doi: 10.1002/ppul.21099.

20.

Hyaluronan blocks porcine pancreatic elastase-induced mucociliary dysfunction in allergic sheep.

Scuri M, Sabater JR, Abraham WM.

J Appl Physiol (1985). 2007 Jun;102(6):2324-31. Epub 2007 Mar 29.

21.

A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure.

Senni M, Santilli G, Parrella P, De Maria R, Alari G, Berzuini C, Scuri M, Filippi A, Migliori M, Minetti B, Ferrazzi P, Gavazzi A.

Am J Cardiol. 2006 Oct 15;98(8):1076-82. Epub 2006 Aug 30.

PMID:
17027575
22.

Peptide and non-peptide bradykinin receptor antagonists: role in allergic airway disease.

Abraham WM, Scuri M, Farmer SG.

Eur J Pharmacol. 2006 Mar 8;533(1-3):215-21. Epub 2006 Feb 7. Review.

PMID:
16455073
23.

Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep.

Scuri M, Abraham WM.

Pulm Pharmacol Ther. 2003;16(6):335-40.

PMID:
14580924
24.

Recombinant alpha 1-proteinase inhibitor blocks antigen- and mediator-induced airway responses in sheep.

Scuri M, Botvinnikova Y, Lauredo IT, Abraham WM.

J Appl Physiol (1985). 2002 Dec;93(6):1900-6.

25.

Hyaluronic acid blocks porcine pancreatic elastase (PPE)-induced bronchoconstriction in sheep.

Scuri M, Abraham WM, Botvinnikova Y, Forteza R.

Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1855-9.

PMID:
11734436
26.

Inhaled porcine pancreatic elastase causes bronchoconstriction via a bradykinin-mediated mechanism.

Scuri M, Forteza R, Lauredo I, Sabater JR, Botvinnikova Y, Allegra L, Abraham WM.

J Appl Physiol (1985). 2000 Oct;89(4):1397-402.

27.

The lactoperoxidase system functions in bacterial clearance of airways.

Gerson C, Sabater J, Scuri M, Torbati A, Coffey R, Abraham JW, Lauredo I, Forteza R, Wanner A, Salathe M, Abraham WM, Conner GE.

Am J Respir Cell Mol Biol. 2000 Jun;22(6):665-71.

PMID:
10837362
28.

The effects of multiple dosing with zileuton on antigen-induced responses in sheep.

Scuri M, Allegra L, Abraham WM.

Pulm Pharmacol Ther. 1998;11(4):277-80.

PMID:
10101744
29.

ET-1 induces mitogenesis in ovine airway smooth muscle cells via ETA and ETB receptors.

Carratu P, Scuri M, Styblo JL, Wanner A, Glassberg MK.

Am J Physiol. 1997 May;272(5 Pt 1):L1021-4.

PMID:
9176269
30.

Inhaled tryptase causes bronchoconstriction in sheep via histamine release.

Molinari JF, Scuri M, Moore WR, Clark J, Tanaka R, Abraham WM.

Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):649-53.

PMID:
8810600
31.

Effect of inhaled and intravenous acetylcholine on bronchial blood flow in anesthetized sheep.

Scuri M, McCaskill V, Chediak AD, Abraham WM, Wanner A.

J Appl Physiol (1985). 1996 Jan;80(1):341-44.

PMID:
8847325
32.

Measurement of airway mucosal blood flow with dimethylether: validation with microspheres.

Scuri M, McCaskill V, Chediak AD, Abraham WM, Wanner A.

J Appl Physiol (1985). 1995 Oct;79(4):1386-90.

PMID:
8567587
33.

The protective effect of transdermal broxaterol on exercise-induced bronchoconstriction.

Robuschi M, Scuri M, Spagnotto S, Gambaro G, Lodola E, Pisati R, Bianco S.

Eur J Clin Pharmacol. 1995;47(5):465-6. No abstract available.

PMID:
7720771
34.

Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin.

Bianco S, Robuschi M, Petrigni G, Scuri M, Pieroni MG, Refini RM, Vaghi A, Sestini PS.

Drugs. 1993;46 Suppl 1:115-20. Review.

PMID:
7506148
35.

Bronchodilating activity of broxaterol transdermal patch and its protective effect on bronchial constriction induced by inhaled distilled water mist.

Robuschi M, Gambaro G, Spagnotto S, Scuri M, Fai V, Lodola E, Pisati R, Bianco S.

Int J Clin Pharmacol Ther Toxicol. 1991 Oct;29(10):407-11.

PMID:
1684178

Supplemental Content

Support Center